Literature DB >> 16714073

Importance of HLA-DQ and HLA-DP polymorphisms in cytokine responses to naturally processed HLA-DR-derived measles virus peptides.

Inna G Ovsyannikova1, Robert A Vierkant, Gregory A Poland.   

Abstract

We studied the association between class II human leukocyte antigen (HLA)-DRB1*0301 presented measles virus (MV) peptide-specific cytokine responses and DQB1 and DPB1 alleles among 313 individuals who received two doses of measles-mumps-rubella-II vaccine. The overall median IFN-gamma secretion levels (first and third quartiles) for the 19-amino acid MV phosphoprotein (MV-P)- and 14-amino acid MV nucleoprotein (MV-N)-derived peptides were 27.7 pg/ml (1.8, 109.4) and 1.9 pg/ml (-6.2, 13.0), respectively; median IL-4 secretion levels were -0.6 pg/ml (-7.1, 6.2) and 2.4 pg/ml (-3.2, 9.3), respectively. Primary statistical analyses were adjusted for previously identified DRB1 associations. A marginally significant increase in the frequency of the DQB1*0604 (p=0.02) allele was found among subjects who demonstrated detectable IL-4 levels to the MV-P peptide. Further, DPB1*0201 (p=0.02) and DPB1*1301 (p=0.09) alleles provided suggestive evidence of an association with MV-P-induced IL-4 secretion. Examination of IFN-gamma responses to MV-P and MV-N indicated that none of the individual alleles of the DQB1 and DPB1 loci were associated with peptide-induced T cell response. An increase in the frequency of DPB1*0501 (p=0.01) was found among subjects who failed to produce MV-N peptide-specific IL-4 responses. These data further confirm that HLA-DRB1 alleles are the major restriction molecules for MV-P and MV-N measles virus antigen presentation to T cells. We speculate that MV-P and MV-N peptides derived from DRB1*0301 could potentially be recognized in association with different HLA molecules, including DQB1 and DPB1; however, statistical adjustments for the effect of HLA-DR locus could potentially alter these genetic relationships. This concept provides important information supporting the use of promiscuous peptides in a peptide-based vaccine approach.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16714073      PMCID: PMC1853367          DOI: 10.1016/j.vaccine.2006.04.034

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  23 in total

1.  HLA polymorphism and T cell recognition of a conserved region of p190, a malaria vaccine candidate.

Authors:  M Guttinger; P Romagnoli; L Vandel; R Meloen; B Takacs; J R Pink; F Sinigaglia
Journal:  Int Immunol       Date:  1991-09       Impact factor: 4.823

2.  Random association between the peptide repertoire of A2.1 class I and several different DR class II molecules.

Authors:  A Sette; A Vitiello; P Farness; J Furze; J Sidney; J M Claverie; H M Grey; R Chesnut
Journal:  J Immunol       Date:  1991-12-01       Impact factor: 5.422

3.  Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells.

Authors:  P Panina-Bordignon; A Tan; A Termijtelen; S Demotz; G Corradin; A Lanzavecchia
Journal:  Eur J Immunol       Date:  1989-12       Impact factor: 5.532

Review 4.  HLA transgenic mice as humanized mouse models of disease and immunity.

Authors:  V Taneja; C S David
Journal:  J Clin Invest       Date:  1998-03-01       Impact factor: 14.808

Review 5.  The biochemistry and cell biology of antigen presentation by MHC class I and class II molecules. Implications for development of combination vaccines.

Authors:  R N Germain
Journal:  Ann N Y Acad Sci       Date:  1995-05-31       Impact factor: 5.691

Review 6.  Modern concepts in immune recognition and lymphocyte activation. Relevance for the development of useful vaccines.

Authors:  R N Germain
Journal:  Int J Technol Assess Health Care       Date:  1994       Impact factor: 2.188

7.  Prediction and identification of a T cell epitope in the fusion protein of measles virus immunodominant in mice and humans.

Authors:  C D Partidos; M W Steward
Journal:  J Gen Virol       Date:  1990-09       Impact factor: 3.891

8.  Use of synthetic peptides to identify measles nucleoprotein T-cell epitopes in vaccinated and naturally infected humans.

Authors:  C J Hickman; A S Khan; P A Rota; W J Bellini
Journal:  Virology       Date:  1997-09-01       Impact factor: 3.616

9.  Differential CD4 T cell activation in measles.

Authors:  D E Griffin; B J Ward
Journal:  J Infect Dis       Date:  1993-08       Impact factor: 5.226

10.  Changes in cytokine production after measles virus vaccination: predominant production of IL-4 suggests induction of a Th2 response.

Authors:  B J Ward; D E Griffin
Journal:  Clin Immunol Immunopathol       Date:  1993-05
View more
  4 in total

Review 1.  HLA-DR: molecular insights and vaccine design.

Authors:  Lawrence J Stern; J Mauricio Calvo-Calle
Journal:  Curr Pharm Des       Date:  2009       Impact factor: 3.116

Review 2.  Genetic studies of African populations: an overview on disease susceptibility and response to vaccines and therapeutics.

Authors:  Giorgio Sirugo; Branwen J Hennig; Adebowale A Adeyemo; Alice Matimba; Melanie J Newport; Muntaser E Ibrahim; Kelli K Ryckman; Alessandra Tacconelli; Renato Mariani-Costantini; Giuseppe Novelli; Himla Soodyall; Charles N Rotimi; Raj S Ramesar; Sarah A Tishkoff; Scott M Williams
Journal:  Hum Genet       Date:  2008-05-30       Impact factor: 4.132

Review 3.  The personal touch: strategies toward personalized vaccines and predicting immune responses to them.

Authors:  Richard B Kennedy; Inna G Ovsyannikova; Nathaniel D Lambert; Iana H Haralambieva; Gregory A Poland
Journal:  Expert Rev Vaccines       Date:  2014-04-04       Impact factor: 5.217

4.  A time transect of exomes from a Native American population before and after European contact.

Authors:  John Lindo; Emilia Huerta-Sánchez; Shigeki Nakagome; Morten Rasmussen; Barbara Petzelt; Joycelynn Mitchell; Jerome S Cybulski; Eske Willerslev; Michael DeGiorgio; Ripan S Malhi
Journal:  Nat Commun       Date:  2016-11-15       Impact factor: 14.919

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.